Sermorelin Sits in a Regulatory Category Most Compounds Don't

Most research peptides sit in one of two regulatory categories. Approved by a drug regulator, or never approved.

Sermorelin sits in a third. It held two full US approvals. Both are gone now. Neither left the market because it stopped working.

Two approvals, for two different things

FDA approved the first of them in December 1990, for a diagnostic test: evaluating whether the pituitary gland's growth-hormone-producing cells can secrete growth hormone on demand. That's a provocative test, not a therapy. It measures a response, it doesn't treat anything.

FDA approved a second application in September 1997, from the same sponsor, for a different purpose entirely: treating idiopathic growth hormone deficiency in children with growth failure. That's a therapeutic approval, for a specific pediatric condition.

Two separate applications, two separate indications, seven years apart. Worth stating precisely, because pages selling this compound routinely cite the 1990 diagnostic approval as though it had endorsed the treatment use. It didn't. The diagnostic approval covered a test. The treatment approval, for one narrow pediatric condition, came later and separately.

Both were withdrawn, by the sponsor, in the same month

In December 2008, the sponsor sent FDA two letters. One requested withdrawal of the therapeutic approval. A second, ten days later, requested withdrawal of the diagnostic approval. FDA withdrew both, effective 18 June 2009.

That's the plain sequence of events. What it doesn't tell you, on its own, is why.

Even the paper trail has documented limits

One further precision worth including, because it fits the same theme as everything above: knowing exactly what the record does and doesn't show.

FDA's own database lists two labeling supplements approved on the diagnostic application, one in March 1998 and one in October 2001. What those labeling changes actually said can't be read from that database today. Approved label text isn't posted there for products withdrawn before 2009, which this one was. The supplements are recorded as having happened. Their content isn't retrievable from that source.

That's a small, specific gap, and it's worth naming rather than glossing over, for the same reason the commercial-reason gap below is worth naming rather than guessing at.

What FDA later said about why

On 4 March 2013, FDA published a formal determination addressing exactly that question. Its own words: these products "were not withdrawn from sale for reasons of safety or effectiveness."

That's not an inference drawn from the absence of a stated reason. It's a specific, dated, published government finding, stating the opposite of what an unexplained withdrawal might otherwise suggest to a reasonable reader.

The determination's own mechanics

The finding didn't originate inside FDA on its own initiative for the therapeutic product. It began with a citizen petition, filed in October 2012 under docket FDA-2012-P-1071, requesting exactly this determination. FDA then extended the finding to the diagnostic product as well, on its own initiative.

The reason this kind of determination exists at all is specific and legal. It's the mechanism that allows a generic version of a withdrawn drug to be approved, once a regulator has confirmed the original wasn't pulled for safety or effectiveness reasons. That's the entire practical purpose of the 2013 finding.

In the thirteen years since, no generic sermorelin product has been filed. FDA's own database lists exactly two applications ever attached to this ingredient, and they're the two original approvals discussed above. No FDA-approved sermorelin product of any kind has existed in the United States since that 18 June 2009 withdrawal date.

Why the products actually left the market is a separate, undocumented question

Worth being precise about a distinction here, because it's easy to blur.

The 2013 finding rules out safety and effectiveness as the reason for withdrawal. It does not supply an alternative reason. The Federal Register notice that records the discontinuation and withdrawal requests gives no commercial rationale at all.

Claims that recombinant growth hormone outcompeted the diagnostic and therapeutic use, or that the raw ingredient became hard to source, do circulate. Neither claim appears in the Federal Register notice or in the Drugs@FDA record. One version of the competition claim does appear in a 2006 editorial, published two years before the withdrawal letters were sent. That's a secondary source, not part of the regulatory record itself. The actual commercial reason for the sponsor's decision is undocumented in the primary regulatory filings, and stating it more confidently than that would be stating more than the record supports.

One name worth separating out, briefly

Sermorelin is also known as GRF(1-29) or GHRH(1-29), which are the same molecule under consistent naming. A similarly named compound, Mod GRF 1-29, sold here as CJC-1295, carries four amino acid substitutions and is a genuinely different molecule, with no approval history of its own. Worth knowing once, so the approval history above stays attached to the right compound, and then set aside.

What actually holds, stated exactly

Both halves of the common shorthand about this compound turn out to be wrong, and they're wrong in opposite directions. "Sermorelin is FDA approved" is false. It hasn't held a current approval since June 2009. "Sermorelin was never FDA approved" is equally false. It held two full, complete, unconditional approvals, spanning the better part of two decades between them. A formal government finding sits on record, stating plainly that neither one ended for the reason a withdrawal usually implies.

That's not a loophole in how the two-category shorthand gets applied. It's a real third category, occupied by a specific compound, with a specific and citable regulatory history behind it. The full research write-up covers what the evidence behind both approvals actually showed.